Amendment dated January 16, 2007

Reply to Office Action of October 16, 2006

**REMARKS/ARGUMENTS** 

Election/Restriction

Claims 51-55 have been withdrawn without prejudice as non-elected claims in response

to a Patent Office restriction requirement.

Objection to the Specification due to an informality

In the Office Action mailed October 16, 2006, the disclosure was objected to for an

informality, i.e., updating the status of the application cross-referenced on page 1 of the

specification. The specification has been amended to provide this update, including

identification by serial number and patent number of the application cross-referenced on page 1

of the specification.

Claim Objection due to an informality

Claim 45 was objected to due to a lack of antecedent basis for the term telemetry

processor. Independent claim 44 has been amended to provide this antecedent basis for the term

telemetry processor.

Claim Rejection – 35 U.S.C. § 102(b)

Claims 44, 46-50, 56 and 58-61 were rejected under 35 U.S.C. 102(b) as being

anticipated by Blanchette et al. (U.S. Patent No. 5,292,343).

Independent claims 44 and 56 have each been amended to claim that "the above steps are

performed in a telemetry processor distinct from a main processor of the device that adjusts

therapy based on the received message." By way of illustration, Fig. 3 of the present application

shows a telemetry module 44 that includes a telemetry processor 62 (see Figs. 5 and 6), which is

6

Amendment dated January 16, 2007

Reply to Office Action of October 16, 2006

distinct from a main processor 34. As noted in the present application, the performing steps in a

telemetry processor distinct from the main processor in an implantable medical device results

under some circumstances in reducing demands on the main processor, conserving energy,

increasing telemetry processing speed and many other advantages. See Abstract and Summary

of the Invention of the present application.

Applicants note that in Notice of Allowability (mailed June 2, 2003) in the parent

application (Serial No. 09/595,971, issued as U.S. Patent No. 6,738,670), the Examiner's

Reasons for Allowance states: "The prior art of record fails to disclose a telemetry processor

comprising the recited control means for operating the telemetry processor according to

instruction stored in memory with the recited decoding and encoding means. The examiner

considers the means-plus-function language of claim 59 to fall under the provision of §112, 6th

paragraph, and therefore be limited to structures disclosed in the specification or equivalents

thereof. Control means for operating a main processor are not considered to be the equivalent of

control means for operating a telemetry processor, as the applicant distinguishes telemetry

processors from main processors. Telemetry processors are taught by the applicant to reduce

demands on the main processor, conserve energy, increase telemetry processing speed, etc. (see

page 2, lines 9-17)."

Blanchette (which was of record in the parent application) does not teach a telemetry

processor distinct from a main processor of the device that adjusts therapy based on the received

message, and thus does not teach any steps performed in a telemetry processor distinct from a

main processor as claimed in claims 44 and 56 as amended. For at least the same reasons that

7

Amendment dated January 16, 2007

Reply to Office Action of October 16, 2006

independent claims 44 and 56 are novel over Blanchette, so are dependent claims 46-50 and 58-

61. In view of the foregoing, it is respectfully submitted that the § 102(b) rejection based on

Blanchette should be withdrawn.

Claim Rejection – 35 U.S.C. § 103(a)

Claims 45 and 57 were rejected under 35 U.S.C. 103(a) as being unpatentable over

Blanchette et al. (U.S. Patent No. 5,292,343) in view of deCoriolis et al. (U.S. Patent No.

5,342,408). The deCoriolis patent (which was of record in the parent application) does not teach

a telemetry processor distinct from a main processor of the device that adjusts therapy based on

the received message, and thus does not teach any steps performed in a telemetry processor

distinct from a main processor. Because deCoriolis does not remedy the deficiencies in

Blanchette, the combination of Blanchette and deCoriolis, even if proper, does not render claims

45 or 57 unpatentable. Claims 45 and 57 are patentable for at least the same reasons that the

independent claims from which they depend are patentable over the prior art.

Conclusion

In view of the foregoing, it is respectfully submitted that pending claims 44-50 and 56-61

are in condition for allowance. The Examiner is invited to contact the undersigned at the

telephone number provided below, should it be deemed necessary to facilitate prosecution of the

application.

8

Amendment dated January 16, 2007

Reply to Office Action of October 16, 2006

Respectfully submitted,

BANNER & WITCOFF, LTD.

Dated: January 16, 2007

By:

Robert H. Resis

Registration No. 32,168 Direct Dial: (312) 463-5405

BANNER & WITCOFF, LTD. 10 S. Wacker Dr., Suite 3000 Chicago, IL 60606-7407

Tel:

(312) 463-5000

Fax:

(312) 463-5001